Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion

Catalysts

About Cochlear

Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss.

What are the underlying business or industry changes driving this perspective?

• The rapid Nexa rollout, with over 80% of developed market implant sales already on the new platform by December and low single digit price uplift achieved in key markets, positions the cochlear implants segment for higher revenue per unit and improved earnings once launch costs and higher initial COGS normalize.
• Growing awareness of the link between hearing loss, cognition and dementia, supported by independent studies and new cognition focused messaging, can expand adult and senior candidacy and referral rates, which would increase implant volumes and support long term revenue growth.
• Cloud migration and unified data architecture, including AI ready platforms, are aimed at more scalable processes and better commercial insights, which can support operating leverage and potentially improve net margins as revenue scales.
• Restructured, more modular R&D focused on complex system capabilities and future technologies like totally implantable cochlear implants and drug eluting electrodes is intended to sustain product differentiation, supporting pricing power and long term earnings resilience.
• Refocused commercial resources on growth, including direct to consumer activity and deeper engagement with the medical referral channel, together with strong execution in large emerging markets such as China despite volume based pricing, can support higher global unit volumes and a broader services and upgrades base, which is important for recurring revenue and profit.

Assumptions

This narrative explores a more optimistic perspective on Cochlear compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Cochlear's revenue will grow by 14.4% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 14.8% today to 20.5% in 3 years time.
• The bullish analysts expect earnings to reach A$717.1 million (and earnings per share of A$10.95) by about February 2029, up from A$345.3 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as A$542.5 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 39.6x on those 2029 earnings, up from 37.7x today. This future PE is greater than the current PE for the AU Medical Equipment industry at 37.4x.
• The bullish analysts expect the number of shares outstanding to decline by 0.09% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.52%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Price pressure from China volume based pricing and a mix shift toward lower tier products in emerging markets may persist over time, which could cap average selling prices for implants and upgrades and weigh on revenue and gross margin.
• Competitors have already used discounting and new product launches to win hospital contracts in cochlear implants and acoustics, and if hospitals keep prioritising lower priced alternatives or alternative MRI compatible devices, Cochlear could lose further share, which would affect unit volumes and earnings.
• Rising input costs from higher initial Nexa COGS, the ongoing Chengdu manufacturing ramp up and continued cloud and R&D investment, together with a target to keep R&D near 12% to 13% of sales, could limit operating leverage and keep net margins below the optimistic assumptions.
• FX exposure to a stronger Australian dollar, which management currently estimates as a A$30m net profit headwind for the second half if rates hold, may remain a structural drag on translated earnings and net margins if currency levels stay elevated for several years.
• If long term growth in adult and senior implants, upgrades and services is slower than management hopes because referrals from hearing aid providers and the medical channel do not accelerate, or payers continue to scrutinise upgrade approvals, revenue growth in developed markets could sit below bullish expectations and lead to lower earnings than currently forecast.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Cochlear is A$350.0, which represents up to two standard deviations above the consensus price target of A$289.85. This valuation is based on what can be assumed as the expectations of Cochlear's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$350.0, and the most bearish reporting a price target of just A$216.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be A$3.5 billion, earnings will come to A$717.1 million, and it would be trading on a PE ratio of 39.6x, assuming you use a discount rate of 7.5%.
  
• Given the current share price of A$199.22, the analyst price target of A$350.0 is 43.1% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.